pioglitazone hydrochloride: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
pioglitazone hydrochloride: clinical details
Prescribing considerations
- Confirm that the licensed treatment setting applies and document baseline glycaemic control.
- Assess heart-failure and bladder-cancer risk factors, especially in older adults.
- Consider fracture risk and the possibility of resumed ovulation in people with polycystic ovary syndrome.
- Reassess clinical benefit early in treatment and periodically thereafter; discontinue if response is inadequate or cardiac status deteriorates.
Contraindications and cautions
- Current or previous cardiac failure
- Hepatic impairment
- Diabetic ketoacidosis
- Current or previous bladder cancer
- Uninvestigated visible haematuria
- Hypersensitivity to pioglitazone or an excipient
Monitoring
- Before treatment: HbA1c, liver function, weight and urinalysis for visible haematuria.
- During treatment: glycaemic response, weight, oedema and symptoms of heart failure.
- Check liver function periodically and promptly if symptoms of hepatic dysfunction develop.
- Assess new urinary symptoms or haematuria and refer visual deterioration for ophthalmological assessment.
Clinical pharmacology
Pioglitazone is a PPAR-gamma agonist that reduces insulin resistance. It undergoes extensive hepatic metabolism, predominantly through CYP2C8, and has active metabolites.
Formulation and product differences
- The selected product is an uncoated oral tablet containing lactose monohydrate.
- Tablet appearance, excipients, packaging and storage instructions may differ between manufacturers; verify the supplied product information.
pioglitazone hydrochloride preparations and strengths
Tablet
Route: Oral
Strengths: 15 mg, 30 mg, 45 mg
pioglitazone hydrochloride interactions
Tell the prescriber or pharmacist about all prescribed, over-the-counter and herbal products. Important examples include:
Insulin
Combined use increases fluid retention, heart-failure and hypoglycaemia risks, so closer clinical monitoring may be needed.
Sulfonylureas
The combination can increase the likelihood of low blood sugar.
Gemfibrozil
It inhibits CYP2C8 and can substantially increase pioglitazone exposure and adverse effects.
Rifampicin
It induces CYP2C8 and can reduce pioglitazone exposure, potentially weakening glucose control.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.